Inhibikase Therapeutics (NYSE:IKT) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Inhibikase Therapeutics (NYSE:IKTGet Rating) released its quarterly earnings results on Monday. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02), MarketWatch Earnings reports. Inhibikase Therapeutics had a negative net margin of 476.81% and a negative return on equity of 43.28%.

IKT opened at $0.70 on Tuesday. The stock’s 50 day simple moving average is $1.21 and its 200-day simple moving average is $1.44. Inhibikase Therapeutics has a 1 year low of $0.66 and a 1 year high of $6.41.

Several large investors have recently modified their holdings of the company. Renaissance Technologies LLC bought a new stake in shares of Inhibikase Therapeutics during the fourth quarter valued at approximately $296,000. Millennium Management LLC acquired a new position in shares of Inhibikase Therapeutics in the third quarter valued at approximately $192,000. State Street Corp bought a new position in Inhibikase Therapeutics during the 4th quarter worth about $84,000. Geode Capital Management LLC grew its holdings in shares of Inhibikase Therapeutics by 206.3% during the fourth quarter. Geode Capital Management LLC now owns 79,128 shares of the company’s stock worth $116,000 after buying an additional 53,295 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Inhibikase Therapeutics by 10.7% in the first quarter. Vanguard Group Inc. now owns 530,098 shares of the company’s stock valued at $785,000 after purchasing an additional 51,394 shares during the last quarter. Institutional investors own 24.49% of the company’s stock.

About Inhibikase Therapeutics (Get Rating)

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects.

See Also

Earnings History for Inhibikase Therapeutics (NYSE:IKT)

Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with's FREE daily email newsletter.